N-({1-[4-(2-naphthyl)pyrimidin-2-yl]piperidin-4-yl}methyl)acetamide | 1123235-48-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-({1-[4-(2-naphthyl)pyrimidin-2-yl]piperidin-4-yl}methyl)acetamide
• 英文别名: N-((1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methyl)acetamide；N-[[1-(4-naphthalen-2-ylpyrimidin-2-yl)piperidin-4-yl]methyl]acetamide
• CAS: 1123235-48-2
• 化学式: C₂₂H₂₄N₄O
• 分子量: 360.459
• InChiKey: BIJLDOOVHGOJNC-UHFFFAOYSA-N

物化性质

• 密度：
  1.171±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-[4-(2-萘基)-2-嘧啶基]-4-哌啶甲胺 、 乙酸酐 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以83%的产率得到N-({1-[4-(2-naphthyl)pyrimidin-2-yl]piperidin-4-yl}methyl)acetamide
  参考文献：
  名称：

  (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: A Wingless β-Catenin Agonist That Increases Bone Formation Rate

  摘要：

  A high-throughput screening campaign to discover small molecule leads for the treatment of bone disorders concluded with the discovery of a compound with a 2-aminopyrimidine template that targeted the Wnt beta-catenin cellular messaging system. Hit-to-lead in vitro optimization for target activity and molecular properties led to the discovery of (1-(4-(naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine (5, WAY-262611). Compound 5 has excellent pharmacokinetic properties and showed a dose dependent increase in the trabecular bone formation rate in ovariectomized rats following oral administration.

  DOI：

  10.1021/jm9014197

文献信息

• NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
  申请人：Pelletier Jeffrey Claude

  公开号：US20090054392A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.

  本发明涉及萘基嘧啶类似物、制备萘基嘧啶类似物的方法、包含萘基嘧啶类似物的组合物以及治疗与经典Wnt-β-catenin细胞信息传递系统相关的疾病的方法，包括向需要治疗的受试者投予有效量的萘基嘧啶、萘基吡嗪和萘基吡啶类似物。
• [EN] NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM<br/>[FR] ANALOGUES DE NAPHTYLPYRIMIDINE, NAPHTYLPYRAZINE ET NAPHTYLPYRIDAZINE ET LEUR UTILISATION COMME AGONISTES DU SYSTÈME DE COMMUNICATION CELLULAIRE WNT-BÊTA-CATÉNINE
  申请人：WYETH CORP

  公开号：WO2009026319A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-[beta-symbol]-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.
• [EN] NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM<br/>[FR] ANALOGUES DE LA NAPHTHYLPYRIMIDINE, DE LA NAPHTHYLPYRAZINE ET DE LA NAPHTHYLPYRIDAZINE ET LEUR UTILISATION EN TANT QU'AGONISTES DU SYSTÈME DE MESSAGERIE CELLULAIRE WNT-BÊTA-CATÉNINE
  申请人：WYETH CORP

  公开号：WO2009026326A1

  公开（公告）日：2009-02-26

  The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-[beta-symbol]-catenin cellular messaging system-related disorders comprising administering to a subject in need thereof an effective amount of a naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analog.